



TML: CS: BSE/NSE CORR: 2020-21

06th July, 2020

BSE Limited,
P. J. Towers, Dalal Street,
Mumbai-400001

**National Stock Exchange of India
Ltd.**

"Exchange Plaza",
Bandra – Kurla Complex,
Bandra – East, Mumbai- 400 051

Dear Sir/Madam,

Sub: Compliance under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: 1. BSE Scrip Code: 530199
2. NSE Scrip Code: THEMISMED

In terms of Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions on a consolidated basis for the half year ended March 31, 2020.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Themis Medicare Limited.**



Sangameshwar Iyer
Company Secretary & Compliance Officer

Themis Medicare Limited

Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India

***Tel.:** 91-22-67607080 ***Fax:** 91-22-67607070/ 28746621

Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat

CIN No.: L24110GJ1969PLC001590 ***Tel/ Fax No.:** **Regd. Off.:** 0260-2431447/ 2430219

***E-mail:** themis@themismedicare.com ***Website:** www.themismedicare.com

THEMIS MEDICARE LIMITED**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD OCTOBER 2019 TO MARCH 2020****RELATED PARTY TRANSACTIONS****(i) List of related parties as per the requirements of Ind-AS 24 - Related Party Disclosures**

Name of Related Party	Country of Incorporation
Associate	
Long Island Nutrionals Private Limited	India
Gujarat Themis Biosyn Limited	India
Joint Venture	
Richter Themis Medicare (India) Private Limited	India
Enterprises over which KMPs are able to exercise significant influence	
Themis Distribution Private Limited	India
Vividh Distributors Private Limited	India
Vividh Margi Investments Private Limited	India
Key Managerial Personnel	
Dr. Dinesh S. Patel (Executive Vice Chairman)	
Dr. Sachin D. Patel (Managing Director and CEO)	
Jayshree D. Patel	
Tushar J. Dalal (Chief Financial Officer)	
Sangameshwar Iyer (Company Secretary)	
Humayun Dhanrajgir (Director)	
Vijay Gopi Kishan Agarwal (Director)	
Hoshang Noshirwan Sinor (Director)	
Rajneesh Kedarnath Anand (Director)	
Hariharan Subramaniam (Director)	
Lajos Kovacs (Director)	
Gulaszi Mihaly Gabor (Director)	
Relatives of Key Managerial Personnel	
Reena S. Patel	

(ii) Transactions with related parties

The following transactions occurred with related parties

(Amount in INR Lakhs)

Name	Nature of Transaction	01/10/2019 to 31/03/2020
Vividh Distributors Private Limited	Sale of finished goods (gross)	357.24
	Freight and other Expenses	1.02
Themis Distribution Private Limited	Sale of finished goods (gross)	3,693.30
	Freight and other Expenses	1.21
Vividh Margi Investments Private Limited	Sale of finished goods (gross)	251.32
	Freight and other Expenses	0.54
	Electricity Charges	2.43
	Telephone Charges	0.01
Richter Themis Medicare (India) Private Limited	Purchase of goods	11.40
Gujurat Themis Biosyn Limited	Sale of finished goods (gross)	0.95

THEMIS MEDICARE LIMITED**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD OCTOBER 2019 TO MARCH 2020****(iii) Outstanding balances****(Amount in INR Lakhs)**

Name	March 31, 2020
Trade Receivables	
Vividh Distributors Private Limited	62.40
Themis Distribution Private Limited	4,402.97
Vividh Margi Investments Private Limited	(21.88)
Richter Themis Medicare (India) Private Limited (Vapi)	38.09
Gujarat Themis Biosyn Limited (Vapi)	(9.05)
Trade Payables	
Richter Themis Medicare (India) Private Limited (Haridwar)	70.42
Gujarat Themis Biosyn Limited (Artemis Biotech)	132.23

(iv) Key management personnel compensation

Short term employee benefits	01/10/2019 to 31/03/2020
Short term employee benefits	117.55
Post-employment benefits	-
Long term employee benefits*	-
Directors sitting fees	5.60
Employee share based payment	-
	123.15

* The amounts of Long term employee benefits cannot be separately identified from the composite amount advised by the actuary/valuer.

(v) Terms and conditions of transactions with related parties

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions and in the ordinary course of business. Outstanding balances at the year end are unsecured and interest free and settlement occurs in cash. For the year ended March 31, 2020, the Company has not recorded any impairment of receivables relating to amount owed by related parties (March 31, 2019: NIL). This assessment is undertaken each financial year through examining the financial position of the related party and market in which the related party operates.